Pharmacotherapy of asthma:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York [u.a.]
Taylor & Francis
2006
|
| Schriftenreihe: | Lung biology in health and disease
212 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | xvi, 400 S. Ill. 24 cm |
| ISBN: | 0849337100 9780849337109 |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV021298010 | ||
| 003 | DE-604 | ||
| 005 | 20060828 | ||
| 007 | t | ||
| 008 | 060118s2006 xxua||| |||| 00||| eng d | ||
| 010 | |a 2005053820 | ||
| 020 | |a 0849337100 |c alk. paper |9 0-8493-3710-0 | ||
| 020 | |a 9780849337109 |9 978-0-8493-3710-9 | ||
| 035 | |a (OCoLC)230770099 | ||
| 035 | |a (DE-599)BVBBV021298010 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-12 |a DE-355 | ||
| 050 | 0 | |a RC591 | |
| 084 | |a XI 4200 |0 (DE-625)153004:12905 |2 rvk | ||
| 084 | |a YB 6415 |0 (DE-625)153148:12921 |2 rvk | ||
| 245 | 1 | 0 | |a Pharmacotherapy of asthma |c ed. by James T. Li |
| 264 | 1 | |a New York [u.a.] |b Taylor & Francis |c 2006 | |
| 300 | |a xvi, 400 S. |b Ill. |c 24 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Lung biology in health and disease |v 212 | |
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a aAsthma xChemotherapy | |
| 650 | 4 | |a aAsthma xdrug therapy | |
| 650 | 4 | |a Asthma |x Chemotherapy | |
| 650 | 4 | |a Asthma |x drug therapy | |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Bronchialasthma |0 (DE-588)4069674-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antiasthmatikum |0 (DE-588)4201239-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Bronchialasthma |0 (DE-588)4069674-1 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antiasthmatikum |0 (DE-588)4201239-9 |D s |
| 689 | 1 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 1 | |C b |5 DE-604 | |
| 700 | 1 | |a Li, James T. C. |e Sonstige |4 oth | |
| 830 | 0 | |a Lung biology in health and disease |v 212 |w (DE-604)BV000008326 |9 212 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014618756&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014618756 | ||
Datensatz im Suchindex
| _version_ | 1804135094240149504 |
|---|---|
| adam_text | Contents
Introduction
Preface
Contributors
1.
David I. Bernstein
I. Introduction
II. Review of NHLBI and GINA Asthma
Treatment Guidelines
III. Impact of Guidelines on Asthma Outcomes
IV. Unresolved Issues and Future Directions
References
2. ß-Agonists .................................. 29
Dave Singh and Ashley Woodcock
I. Introduction
II. The
III. Pharmacology of
xi
xii Contents
IV.
V. Long-Acting
VI. Influence of Genotype on
VII.
Abbreviations
References
3.
Nicholas J. Gross
I. Introduction
II. Rationale for Use of Anticholinergic
Bronchodilators
III. Pharmacology
IV. Clinical Efficacy
V. Side Effects
VI. Clinical Recommendations
References
4.
of Asthma in Adults
Matthew Masoli, Philippa Shirtcliffe, Shaun Holt,
Mark Weatherall, and Richard Beasley
I. Reduction in Airways Inflammation
II. Reduction in Bronchial Responsiveness
III. Clinical Efficacy
IV. Dose-Response Relationships
V. Systemic Side Effects
VI. Frequency of Administration
VII.
VIII.
IX. Early Intervention
X. Add-On Therapy with a Long-Acting
ß-Agonist .... 97
XI. Alternative Add-On Therapy
XII.
Plan System of Care
XIII.
XIV.
References
Contents xiii
5. Optimal Management
Leukotriene
Michael E. Wechsler
I. Introduction
II. Historical Perspectives and the Rational Scientific
Basis for Leukotriene Modifiers in Asthma
III. Leukotriene Modifiers Are Effective in Several
Types of Asthma
IV. Leukotriene Modifiers: Safety
Considerations
V. Conclusions: The Role of Leukotriene Modifiers in the
Treatment of Asthma and Future Directions
VI. Summary
References
6.
Miles Weinberger
I. History
II. Pharmacological Activities Potentially Relevant for
Asthma
III. Molecular Mechanisms
IV. Pharmacodynamics
V. Biopharmaceutics and Pharmacokinetics
VI. Clinical Usage
VII.
VIII.
Inhibitors
IX. Summary
References
7.
Margaret Lowery and Kevin J. Kelly
I. Introduction
II. Historical Background
III. Pharmacokinetics
IV. Drug Distribution in the Lung
V. Cromone Mechanism of Action
VI. Immunoregulatory Effects
VII. Neurogenic
VIII.
xiv Contents
IX.
X. Nedocromil for
XI.
XII. Cromolyn
XIII.
XIV.
References
8.
Ruth H. Green and Andrew J. Wardlaw
I. Introduction
II. Review of Pharmacology
III. Mechanisms of Action
IV. Clinical Effects in Asthma
V. Safety
VI. Recommendations
References
9.
S.
I. Introduction
II. What Is IgE?
III. Anti-IgE as a Therapeutic Strategy
IV. Anti-IgE Therapy with Omalizumab
Concept
V. Pivotal Studies in Asthma
VI. Selecting Patients for Anti-IgE Therapy
with Omalizumab
VII.
VIII.
IX. Tolerability of Omalizumab
X. Future Directions
References
10.
Asthma
Mark S. Dykewicz
I. Introduction
II. Patient Candidates for Alternate Asthma
Treatments
Contents xv
HI. Caveats in Interpreting
IV. Gold
V. Methotrexate
VI. Azathioprine
VII. Hydroxychloroquine
VIH.
IX. Nebulized Lidocaine
X. Inhaled Furosemide
XI. Cyclosporine
XII.
XIII.
XIV.
References
11.
Anthony J. Frew
I. Introduction
II. Specific Allergen Immunotherapy for
Asthma
III. SIT to Prevent Asthma
IV. SIT to Manage Established Asthma
V. Comparison of SIT with Other Types of
Treatment for Asthma
VI. Risks of Allergen Immunotherapy
in Asthma
VII.
VIII.
References
12.
Guy
I. Introduction
II. Reliever Therapy
III. Maintenance Pharmacotherapy
IV. Future Prospects of Asthma
Pharmacotherapy
V. Conclusion
Abbreviations
References
xvi Contents
13.
Hospital Floor, and Intensive Care Unit
Ajeet G. Vinayak, J. P. Kress, and Jesse Hall
I. Introduction
II. Epidemiology
III. Emergency Department Assessment
IV. Emergency Department Therapy
V. ED Disposition
VI. Hospital Ward Care
VII. ICU
VIII.
References
Index
|
| adam_txt |
Contents
Introduction
Preface
Contributors
1.
David I. Bernstein
I. Introduction
II. Review of NHLBI and GINA Asthma
Treatment Guidelines
III. Impact of Guidelines on Asthma Outcomes
IV. Unresolved Issues and Future Directions
References
2. ß-Agonists . 29
Dave Singh and Ashley Woodcock
I. Introduction
II. The
III. Pharmacology of
xi
xii Contents
IV.
V. Long-Acting
VI. Influence of Genotype on
VII.
Abbreviations
References
3.
Nicholas J. Gross
I. Introduction
II. Rationale for Use of Anticholinergic
Bronchodilators
III. Pharmacology
IV. Clinical Efficacy
V. Side Effects
VI. Clinical Recommendations
References
4.
of Asthma in Adults
Matthew Masoli, Philippa Shirtcliffe, Shaun Holt,
Mark Weatherall, and Richard Beasley
I. Reduction in Airways Inflammation
II. Reduction in Bronchial Responsiveness
III. Clinical Efficacy
IV. Dose-Response Relationships
V. Systemic Side Effects
VI. Frequency of Administration
VII.
VIII.
IX. Early Intervention
X. Add-On Therapy with a Long-Acting
ß-Agonist . 97
XI. Alternative Add-On Therapy
XII.
Plan System of Care
XIII.
XIV.
References
Contents xiii
5. Optimal Management
Leukotriene
Michael E. Wechsler
I. Introduction
II. Historical Perspectives and the Rational Scientific
Basis for Leukotriene Modifiers in Asthma
III. Leukotriene Modifiers Are Effective in Several
Types of Asthma
IV. Leukotriene Modifiers: Safety
Considerations
V. Conclusions: The Role of Leukotriene Modifiers in the
Treatment of Asthma and Future Directions
VI. Summary
References
6.
Miles Weinberger
I. History
II. Pharmacological Activities Potentially Relevant for
Asthma
III. Molecular Mechanisms
IV. Pharmacodynamics
V. Biopharmaceutics and Pharmacokinetics
VI. Clinical Usage
VII.
VIII.
Inhibitors
IX. Summary
References
7.
Margaret Lowery and Kevin J. Kelly
I. Introduction
II. Historical Background
III. Pharmacokinetics
IV. Drug Distribution in the Lung
V. Cromone Mechanism of Action
VI. Immunoregulatory Effects
VII. Neurogenic
VIII.
xiv Contents
IX.
X. Nedocromil for
XI.
XII. Cromolyn
XIII.
XIV.
References
8.
Ruth H. Green and Andrew J. Wardlaw
I. Introduction
II. Review of Pharmacology
III. Mechanisms of Action
IV. Clinical Effects in Asthma
V. Safety
VI. Recommendations
References
9.
S.
I. Introduction
II. What Is IgE?
III. Anti-IgE as a Therapeutic Strategy
IV. Anti-IgE Therapy with Omalizumab
Concept
V. Pivotal Studies in Asthma
VI. Selecting Patients for Anti-IgE Therapy
with Omalizumab
VII.
VIII.
IX. Tolerability of Omalizumab
X. Future Directions
References
10.
Asthma
Mark S. Dykewicz
I. Introduction
II. Patient Candidates for Alternate Asthma
Treatments
Contents xv
HI. Caveats in Interpreting
IV. Gold
V. Methotrexate
VI. Azathioprine
VII. Hydroxychloroquine
VIH.
IX. Nebulized Lidocaine
X. Inhaled Furosemide
XI. Cyclosporine
XII.
XIII.
XIV.
References
11.
Anthony J. Frew
I. Introduction
II. Specific Allergen Immunotherapy for
Asthma
III. SIT to Prevent Asthma
IV. SIT to Manage Established Asthma
V. Comparison of SIT with Other Types of
Treatment for Asthma
VI. Risks of Allergen Immunotherapy
in Asthma
VII.
VIII.
References
12.
Guy
I. Introduction
II. Reliever Therapy
III. Maintenance Pharmacotherapy
IV. Future Prospects of Asthma
Pharmacotherapy
V. Conclusion
Abbreviations
References
xvi Contents
13.
Hospital Floor, and Intensive Care Unit
Ajeet G. Vinayak, J. P. Kress, and Jesse Hall
I. Introduction
II. Epidemiology
III. Emergency Department Assessment
IV. Emergency Department Therapy
V. ED Disposition
VI. Hospital Ward Care
VII. ICU
VIII.
References
Index |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV021298010 |
| callnumber-first | R - Medicine |
| callnumber-label | RC591 |
| callnumber-raw | RC591 |
| callnumber-search | RC591 |
| callnumber-sort | RC 3591 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XI 4200 YB 6415 |
| ctrlnum | (OCoLC)230770099 (DE-599)BVBBV021298010 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02146nam a2200553zcb4500</leader><controlfield tag="001">BV021298010</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20060828 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060118s2006 xxua||| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2005053820</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0849337100</subfield><subfield code="c">alk. paper</subfield><subfield code="9">0-8493-3710-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780849337109</subfield><subfield code="9">978-0-8493-3710-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)230770099</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021298010</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC591</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4200</subfield><subfield code="0">(DE-625)153004:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YB 6415</subfield><subfield code="0">(DE-625)153148:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacotherapy of asthma</subfield><subfield code="c">ed. by James T. Li</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Taylor & Francis</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xvi, 400 S.</subfield><subfield code="b">Ill.</subfield><subfield code="c">24 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Lung biology in health and disease</subfield><subfield code="v">212</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aAsthma xChemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aAsthma xdrug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bronchialasthma</subfield><subfield code="0">(DE-588)4069674-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antiasthmatikum</subfield><subfield code="0">(DE-588)4201239-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Bronchialasthma</subfield><subfield code="0">(DE-588)4069674-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antiasthmatikum</subfield><subfield code="0">(DE-588)4201239-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, James T. C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Lung biology in health and disease</subfield><subfield code="v">212</subfield><subfield code="w">(DE-604)BV000008326</subfield><subfield code="9">212</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014618756&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014618756</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV021298010 |
| illustrated | Illustrated |
| index_date | 2024-07-02T13:51:49Z |
| indexdate | 2024-07-09T20:35:02Z |
| institution | BVB |
| isbn | 0849337100 9780849337109 |
| language | English |
| lccn | 2005053820 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014618756 |
| oclc_num | 230770099 |
| open_access_boolean | |
| owner | DE-12 DE-355 DE-BY-UBR |
| owner_facet | DE-12 DE-355 DE-BY-UBR |
| physical | xvi, 400 S. Ill. 24 cm |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Taylor & Francis |
| record_format | marc |
| series | Lung biology in health and disease |
| series2 | Lung biology in health and disease |
| spelling | Pharmacotherapy of asthma ed. by James T. Li New York [u.a.] Taylor & Francis 2006 xvi, 400 S. Ill. 24 cm txt rdacontent n rdamedia nc rdacarrier Lung biology in health and disease 212 Includes bibliographical references and index aAsthma xChemotherapy aAsthma xdrug therapy Asthma Chemotherapy Asthma drug therapy Pharmakologie (DE-588)4045687-0 gnd rswk-swf Bronchialasthma (DE-588)4069674-1 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Antiasthmatikum (DE-588)4201239-9 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Bronchialasthma (DE-588)4069674-1 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Antiasthmatikum (DE-588)4201239-9 s Pharmakologie (DE-588)4045687-0 s b DE-604 Li, James T. C. Sonstige oth Lung biology in health and disease 212 (DE-604)BV000008326 212 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014618756&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Pharmacotherapy of asthma Lung biology in health and disease aAsthma xChemotherapy aAsthma xdrug therapy Asthma Chemotherapy Asthma drug therapy Pharmakologie (DE-588)4045687-0 gnd Bronchialasthma (DE-588)4069674-1 gnd Pharmakotherapie (DE-588)4076066-2 gnd Antiasthmatikum (DE-588)4201239-9 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4069674-1 (DE-588)4076066-2 (DE-588)4201239-9 (DE-588)4143413-4 |
| title | Pharmacotherapy of asthma |
| title_auth | Pharmacotherapy of asthma |
| title_exact_search | Pharmacotherapy of asthma |
| title_exact_search_txtP | Pharmacotherapy of asthma |
| title_full | Pharmacotherapy of asthma ed. by James T. Li |
| title_fullStr | Pharmacotherapy of asthma ed. by James T. Li |
| title_full_unstemmed | Pharmacotherapy of asthma ed. by James T. Li |
| title_short | Pharmacotherapy of asthma |
| title_sort | pharmacotherapy of asthma |
| topic | aAsthma xChemotherapy aAsthma xdrug therapy Asthma Chemotherapy Asthma drug therapy Pharmakologie (DE-588)4045687-0 gnd Bronchialasthma (DE-588)4069674-1 gnd Pharmakotherapie (DE-588)4076066-2 gnd Antiasthmatikum (DE-588)4201239-9 gnd |
| topic_facet | aAsthma xChemotherapy aAsthma xdrug therapy Asthma Chemotherapy Asthma drug therapy Pharmakologie Bronchialasthma Pharmakotherapie Antiasthmatikum Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014618756&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000008326 |
| work_keys_str_mv | AT lijamestc pharmacotherapyofasthma |